Benzonase® endonuclease acts as an unspecific endonuclease, degrading both DNA and RNA to small 3–5 base pairs (< 6 kDa) fragments with no base preference. It is the ideal tool for nucleic acid removal in virus vector and vaccine manufacturing as demanded by regulators. Additionally, the use of Benzonase® endonuclease increases the yield in virus purification, protects downstream chromatography and filter devices from fouling, and reduces feed stream viscosity.
Benzonase® endonuclease is the smart solution for DNA removal in viral vaccine and viral vector production and has proven its value for over 30 years. Balancing efficiency and regulatory compliance by delivering reliability and high-quality due manufacturing under good manufacturing practices (GMP ICH Q7). Our extensive documentation packages of Emprove® dossiers and the availability of a FDA Drug Master File type II, supports you in filing your vaccine manufacturing process to the authorities.
Used for the removal of nucleic acid from protein samples.
Digests native or heat-denatured DNA and RNA.
Appearance (description): clear
Appearance (color): colourless
Activity (DNA; pH 8.0; 30 min; 37 °C): ≥ 250 U/µl
Spec. activity (calc. on protein): ≥ 1.1E+06 U/mg
Identity (electrophoresis): passes test
Purity (calc. on protein): ≥ 99.0%
Proteases: not detectable
Colony count (aerobic bacteria): <10 CFU in 100 000 U
Colony count (Yeasts and moulds): <10 CFU in 100 000 U
Endotoxines (LAL-test): <0.25 EU in 1000 U
Benzonase is a registered trademark of Merck KGaA, Darmstadt, Germany
Emprove is a registered trademark of Merck KGaA, Darmstadt, Germany